123624-90-8

Basic information

• Product Name: 2-(CHLOROMETHYL)-3,5,6-TRIMETHYLPYRAZINE
• Synonyms: 2-(CHLOROMETHYL)-3,5,6-TRIMETHYLPYRAZINE
• CAS NO: 123624-90-8
• Molecular Formula: C₈H₁₁ClN₂
• Molecular Weight: 170.64
• Mol File: 123624-90-8.mol
• Article Data: 11

Chemical Properties

• Appearance: /
• CAS DataBase Reference: 2-(CHLOROMETHYL)-3,5,6-TRIMETHYLPYRAZINE(CAS DataBase Reference)
• NIST Chemistry Reference: 2-(CHLOROMETHYL)-3,5,6-TRIMETHYLPYRAZINE(123624-90-8)
• EPA Substance Registry System: 2-(CHLOROMETHYL)-3,5,6-TRIMETHYLPYRAZINE(123624-90-8)

Safety Data

• Hazardous Substances Data: 123624-90-8(Hazardous Substances Data)

Usage

General Description

2-(Chloromethyl)-3,5,6-trimethylpyrazine is a chemical compound with the molecular formula C7H10ClN2. It is a pyrazine derivative with a chloromethyl group attached to the pyrazine ring, as well as three methyl groups at different positions. 2-(CHLOROMETHYL)-3,5,6-TRIMETHYLPYRAZINE is commonly used as a flavoring agent in the food industry, adding a savory and roasted aroma to various food products. It is also used in the fragrance industry, contributing to the scent of perfumes and colognes. Additionally, it has been studied for its potential as an insect repellent due to its strong odor. Overall, 2-(Chloromethyl)-3,5,6-trimethylpyrazine has applications in various industries due to its unique odor and flavor properties.

Upstream product

• 79074-43-4 (3,5,6-trimethylpyrazin-2-yl)methyl acetate 
• 1124-11-4 Tetramethylpyrazine 
• 22978-83-2 2,3,5,6-tetramethylpyrazine mono N-oxide 
• 75907-74-3 2-Pyrazinemethanol,3,5,6-trimethyl 

Downstream Products

• 1282538-35-5 2-((4-allyl-2-methoxyphenoxy)methyl)-3,5,6-trimethylpyrazine 
• 947243-87-0 ethyl 3-methoxy-4-[(3,5,6-trimethylpyrazin-2-yl)methoxy]benzoate 
• 947243-90-5 ethyl 2-[(3,5,6-trimethylpyrazin-2-yl)methoxy]benzoate 
• 1000672-70-7 (E)-2-(4-nitrostyryl)-3,5,6-trimethylpyrazine 
• 1000672-69-4 (E)-2-(2,3-dimethoxylstyryl)-3,5,6-trimethylpyrazine 
• 1000672-68-3 (E)-2-(2-hydroxylstyryl)-3,5,6-trimethylpyrazine 
• 1000672-67-2 (E)-2-(3-methoxyl-2-hydroxylstyryl)-3,5,6-trimethylpyrazine 
• 1000672-66-1 (E)-2-(2,5-dimethoxylstyryl)-3,5,6-trimethylpyrazine 
• 1000672-65-0 (E)-2-(4-fluorostyryl)-3,5,6-trimethylpyrazine 
• 1000672-64-9 (E)-2-(3-chlorostyryl)-3,5,6-trimethylpyrazine 
• 1000672-63-8 (E)-2-(3-hydroxylstyryl)-3,5,6-trimethylpyrazine 
• 1000672-89-8 (E)-2-(2-chlorostyryl)-3,5,6-trimethylpyrazine 

Relevant articles and documents

Design, synthesis and evaluation of new ligustrazine derivatives as potential plasma-stable neuroprotective agents

A series of ligustrazine-phenolic acid esters which exhibited promising neuroprotective activities have previously been reported. Nevertheless, we found that these ester compounds (like T-VA) were not stable in plasma by further in vivo studies. To investigate plasma-stable neuroprotective agents, a series of new ligustrazine derivatives were synthesized by conjoining ligustrazine and phenols with ester, ether and amide bonds. Most of the compounds exhibited higher protective effects against CoCl2-induced neurotoxicity in differentiated PC12 cells than ligustrazine. Structure-activity relationships were also briefly discussed. We found that compound 2c (2-((2-methoxy-4-(((3,5,6-trimethylpyrazin-2-yl)methoxy) methyl)phenoxy)methyl)-3,5,6-trimethylpyrazine) displayed the highest protective effect on the PC12 cells damaged by CoCl2 (EC50 = 1.07 μM). Preliminary stability investigation in rat plasma was verified in vitro and better plasma stability was observed with 2c in comparison to T-VA.

Novel homo-bivalent and polyvalent compounds based on ligustrazine and heterocyclic ring as anticancer agents

Bivalent and polyvalent inhibitors can be used as antitumor agents. In this experiment, eight ligustrazine dimers and seven ligustrazine tetramers linked by alkane diamine with different lengths of carbon chain lengths were synthesized. After screening their antiproliferation activities against five cancer cell lines, most ligustrazine derivatives showed better cytotoxicity than the ligustrazine monomer. In particular, ligustrazine dimer 8e linked with decane-1,10-diamine exhibited the highest cytotoxicity in FaDu cells with an IC50 (50% inhibiting concentration) value of 1.36 nM. Further mechanism studies suggested that 8e could induce apoptosis of FaDu cells through the depolarization of mitochondrial membrane potential and S-phase cell cycle arrest. Inspired by these results, twenty-seven additional small molecule heterocyclic dimers linked with decane-1,10-diamine and nine cinnamic acid dimers bearing ether chain were synthesized and screened. Most monocyclic and bicyclic aromatic systems showed highly selective anti-proliferation activity to FaDu cells and low toxicity to normal MCF 10A cells. The structure-activity relationship revealed that the two terminal amide bonds and the alkyl linker with a chain length of 8–12 carbon were two important factors to maintain its antitumor activity. In addition, the ADMET calculation predicted that most of the potent compounds had good oral bioavailability.

Hederagenin compound H-X with anti-lung cancer effect and preparation method and application thereof

The invention provides a hederagenin compound H-X with an anti-tumor effect and a preparation method and application thereof. The structural general formula 1 is shown in the specifications. Most of the derivatives provided by the invention have obvious inhibition effects on tumor cells A549, MCF-7 and HepG2, and the compound hederagenin-2, 6-dimethylpyrazine (H-08) shows good selectivity betweentumors and normal conditions, especially on lung cancer A549 cells. The IC50 of the compound to A549, MCF-7, HepG2, MDCK and H9c2 is 3.45+/-0.59 muM, 8.73+/-1.49 muM, 8.71+/-0.38 muM, 14.11+/-0.04 muM, and 16.69+/-0.12 muM, the inhibition effect on A549 cells is similar to that of a positive drug cis-platinum (IC50 is 3.85+/-0.63 muM), but the toxicity on MDCK and H9c2 is obviously lower than thatof cis-platinum.